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INTRODUCTION
Malignant hilar biliary obstruction (MHBO) is reported in a 
variety of cancers, including cholangiocarcinoma, gallbladder 
cancer, pancreatic cancer, and stomach cancer. There are sev-
eral complications related to biliary obstruction, such as jaun-
dice and cholangitis. Proper management of these complica-
tions is important to improving the prognosis of patients with 
MHBO. Endoscopic biliary drainage with metallic stents has 
been performed for managing those complications, due to its 
minimal invasiveness and long-term patency, compared to 
drainage with plastic stents.1 Recently, bilateral biliary decom-
pression with self-expandable metallic stents (SEMSs) has 
been considered a favorable palliative procedure for unresect-
able MHBO.2,3 
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Purpose: Endoscopic bile duct decompression using bilateral self-expandable metallic stents (SEMSs) deployed via a stent-in-
stent (SIS) method is considered a preferred procedure for malignant hilar biliary obstruction (MHBO). However, occlusion 
thereof occurs frequently. Here, we investigated stent patency duration and risk factors related to stent obstruction with bilateral 
SIS placement for MHBO at two large centers.
Materials and Methods: The present study reviewed data on patients with MHBO who underwent endoscopic biliary drainage 
using the SIS method. Clinical outcomes, including stent patency duration and patient overall survival, were analyzed. Factors as-
sociated with stent patency were evaluated using Cox proportional hazards models.
Results: Seventy patients with MHBO underwent endoscopic biliary drainage using the SIS method. Median age was 68 years 
old, and median follow-up duration was 140 days (interquartile range, 57–329). The proportion of high-grade MHBOs (Bismuth 
type IV) was 57.1%. Median stent patency duration with the SIS method was 108 days according to Kaplan-Meier curves. Median 
patient survival analyzed by the Kaplan-Meier method was 181 days. Multivariate analysis indicated that higher baseline biliru-
bin (> 6.1 mg/dL) as an independent risk factor related to stent patency (p<0.05).
Conclusion: In endoscopic biliary decompression using SEMS placed with the SIS method, obstructive jaundice was a risk factor 
for stent patency. The SIS method for high-grade MHBO showed short stent patency.
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Bilateral stent-in-stent (SIS) SEMS placement is physiologic 
and currently favored by endoscopists despite its technical 
difficulty. Bilateral drainage also offers advantages in preserv-
ing functional volume of the liver and prolonging stent paten-
cy.4-7 SIS placement involves contralateral placement of a sec-
ond SEMS through the mesh of the first deployed stent to 
achieve a physiological Y configuration.8 In terms of SIS meth-
od for endoscopic bilateral metallic stenting in MHBO, previ-
ous studies have reported various stent patency durations 
(median patency duration, 140–240 days).6,9-15 However, en-
doscopists have frequently reported experiencing occlusion 
of Y-shaped metal stents in patients receiving metal stents via 
the SIS method for high-grade MHBO.10,11,16,17
A few studies have delved into risk factors related to stent 
occlusion in patients using the SIS method; however, these 
studies only analyzed a small number of patients with biliary 
obstruction. Accordingly, we reviewed MHBO patients from 
two large-volume centers to investigate stent patency duration 
with SIS method, as well as risk factors associated with stent 
patency.
 
MATERIALS AND METHODS
Patients 
We analyzed patients with MHBO who underwent bilateral SIS 
placement with SEMSs between 2009 and 2016 at two tertiary 
hospitals in South Korea (Severance Hospital and Seoul Na-
tional University Hospital). We included 16 patients from Sev-
erance Hospital and 54 patients from Seoul National University 
Hospital with unresectable MHBO using Bismuth classifica-
tions of II, III, and IV. Unresectability was judged according to 
advanced cancer extension or intolerable condition of patients 
based on computed tomography (CT), or magnetic resonance 
imaging (MRI), cholangiography, and positron emission to-
mography. We excluded patients who 1) were aged <20 years 
or >90 years and 2) had a history of biliary tract operation. This 
study was performed in accordance with ethical guidelines of 
the 1975 Declaration of Helsinki and was approved by the Insti-
tutional Review Boards of Severance Hospital (IRB no. 4-2015-
1072) and Seoul National University (IRB no. H-1303-105-475).
Technique
In this study, endoscopic retrograde cholangiopancreatogra-
phy (ERCP) procedures were performed by eight experienced 
endoscopists with at least 5 years of experience and each hav-
ing performed >1000 ERCP procedures. ERCPs were performed 
under conscious sedation with propofol and pethidine, while 
being monitored by either an anesthesiologist or endoscopist at 
the same time. All ERCPs were conducted according to fluo-
roscopic guidance to diagnose and manage obstruction using 
a large (4.2 mm) accessory channel duodenoscope (TJF-240; 
Olympus Optical Co., Ltd., Tokyo, Japan). Cannulation of the com-
mon bile duct was attempted with a conventional cannula (Con-
tour ERCP cannula; Boston Scientific, Natick, MA, USA) with 
or without a guidewire or with a pull-type sphincterotome 
[Clever-cut (Olympus Optical) or Autotome RX 44 (Boston Sci-
entific)]. A precut papillotomy was attempted upon trial failures 
of wire-guided cannulation using a pull-type sphincterotome. 
After biliary cannulation and completion of cholangiogra-
phy, two 0.035-inch-diameter guidewires were passed through 
the stricture and inserted into the left and right hepatic ducts. 
Location and length of the stricture were evaluated by cholan-
giogram. After identifying location and extent of malignant 
bile duct stricture, endoscopists decided which stents [Niti-S 
large cell D-type stent® (Taewoong Medical, Gimpo, Korea), 
Wallstent® (Boston Scientific Co.), or Hanarostent® (M.I.Tech, 
Pyeongtaek, Korea)] to apply. Two SEMSs were inserted via SIS 
placement. Endoscopic bilateral SIS placement using SEMSs 
was performed as follows: The first stent was inserted and 
slowly deployed into the left intrahepatic duct over the guide-
wire. The second stent was deployed through the mesh of the 
first stent, such that the two stents overlapped in the common 
hepatic duct and branched into hepatic ducts, forming a Y-shape 
(Fig. 1). The lengths of SEMSs were chosen on the basis of the 
maximum size necessary to span the stenotic area; the diam-
eter of SEMSs was 10 mm.
Follow-up and definition
Enrollment was defined as the date of first bilateral stent place-
ment. Before the procedure and during follow up at 2 weeks 
and 4 weeks after the procedure, all patients underwent labo-
ratory testing, including complete blood count and blood bio-
chemistry. Radiological examinations, including abdominal 
ultrasonography, CT, or MRI, were performed at fixed intervals 
(1 or 2 months) or when stent dysfunction was suspected, such 
as elevated total bilirubin or clinical features suggestive of chol-
angitis (e.g., fever with signs of jaundice and right upper quad-
rant pain).
The primary outcome was stent patency duration. Stent pa-
tency duration was defined as the time interval between SEMSs 
insertion and stent occlusion or death. The secondary out-
comes were technical success, functional success, complica-
tions, risk factors related to stent occlusion, and overall survival. 
Technical success was defined as appropriate stent position-
ing at the stricture site and immediate biliary decompression. 
Functional success was defined as a decrease in bilirubin level to 
less than 75% of the pretreatment value within the first month. 
Immediate and early complications, such as cholangitis, pan-
creatitis, and bleeding, were defined as procedure-related com-
plications occurring within 72 h and after 72 h, but within 30 
days of stent placement, respectively. Moreover, late compli-
cations were defined as procedure-related complications oc-
curring after 30 days of stent placement. Stent occlusion was 
suspected in patients with abnormal laboratory parameters, 
such as serum bilirubin, liver transaminase, and/or alkaline 
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phosphatase (ALP), and symptoms, such as jaundice, fever, and/
or abdominal pain. Stent occlusion was diagnosed if patients 
had jaundice with evidence of elevated bilirubin levels and bili-
ary dilation on imaging studies. Tumor ingrowth, tumor over-
growth, hemobilia, and occlusion secondary to sludge or food 
impaction were evaluated as reasons for stent occlusion. If a 
stent was occluded, repeat ERCP was performed to confirm 
the stent patency and manage the occlusion. Stent malfunc-
tion was defined when re-intervention was needed in cases of 
complications, such cholangitis and/or jaundice, elevated liv-
er enzyme levels, and bile duct dilation. In cases of stent mal-
function, a repeat endoscopic procedure for biliary drainage 
was performed using SEMSs or plastic stents. Percutaneous 
transhepatic biliary drainage was performed instead of endo-
scopic procedures only in cases of severe cholangitis that pre-
cluded endoscopy or failed bilateral stent placement. Overall 
survival was calculated from the day of SEMSs insertion to the 
day of last follow-up or death.
Statistical analysis
All data, including stent patency and survival, are expressed as 
a median (±standard deviation) or n (%), as appropriate. Mann-
Whitney U-test was used for comparison of continuous vari-
ables, and chi-square test with Fisher’s exact test was used for 
categorical variables. Cumulative stent patency and survival 
time were estimated using Kaplan-Meier analysis, and curves 
were compared with the log-rank test. To identify indepen-
dent risk factors for stent occlusion and survival, univariate and 
subsequent multivariable Cox regression analyses were per-
formed. All statistical analyses were performed using standard 
software (SPSS v23.0; IBM Corp., Armonk, NY, USA), with 
p<0.05 considered as statistically significant. 
RESULTS
Patient characteristics
Seventy patients with MHBO underwent bilateral SIS place-
ment between November 2009 and July 2016. The clinical 
characteristics of the patients are summarized in Table 1. Their 
median age was 68 years, and 38 patients (53.5%) were men. 
Median values of pre-stenting total bilirubin and pre-stenting 
ALP were 6.1±11.1 mg/dL and 450±355 IU/dL, respectively. 
Among study participants, histopathology was confirmed in 
54 (76.1%) patients, and cancer types were as follows: cholan-
giocarcinoma (n=37, 52.9%), gallbladder cancer (n=22, 31.4%), 
and other cancers (n=11, 15.7%) including pancreatic and ad-
vanced gastric cancers. Bismuth classifications were as fol-
lows: type II (n=13, 18.6%), type III (n=17, 24.3%), and type IV 
(n=40, 57.1%). Among the participants, 35 (50.0%) underwent 
chemotherapy and three (6.4%) underwent radiotherapy after 
bilateral biliary stenting. Twenty-six patients underwent pre-
vious plastic stenting as a temporary placement. One patient 
underwent bilateral biliary stenting after removal of a previ-
ously inserted metal stent. 
Outcomes
Outcomes for patients with bilateral metal stenting are shown 
in Table 2. The technical success rate was 98% (69/70), and the 
functional success rate was 85.5% (59/70). The cause of tech-
nical failure was stent deployment failure. Immediate compli-
cations occurred in nine (12.6%) patients. Four (5.6%) patients 
developed cholangitis, and five (5.6%) patients developed pan-
creatitis within 72 h of stent placement. Early complications 
occurred in eight (11.2%) patients, all of whom developed 
cholangitis within 30 days after of stent placement. Late com-
plications did not occur in any patient. Cholangitis occurred 
Fig. 1. Representative images. (A) Malignant hilar biliary obstruction. (B) Bilateral stent-in-stent placement.
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in four patients as an immediate complication and in eight pa-
tients as an early complication. Ten cases were non-occlusion 
cholangitis and two cases were occlusion cholangitis. Ten pa-
tients underwent intervention, including temporary drainage 
or balloon sweeping, to resolve cholangitis. In two patients, 
cholangitis resolved spontaneously without any intervention. 
Patients with cholangitis and stent occlusion were document-
ed simultaneously in number. During a median follow-up pe-
riod of 140 days, stent occlusion occurred in 35 (50.0%) patients 
due to sludge (n=1), tumor ingrowth (n=29), tumor overgrowth 
(n=2), and unknown reasons (n=3). Seven patients received 
ERCP with sweeping using a basket and balloon, and 13 pa-
tients received stent reinsertion inside of the previously insert-
ed metal stent (plastic stent in four patients and metal stent in 
nine patients). Nineteen patients underwent percutaneous tran-
shepatic biliary drainage with or without stent insertion. Dur-
ing the observation period, no patient (0%) developed stent 
malfunction within 72 h of stent insertion, while three (3.2%) 
patients developed stent malfunction within 30 days after of 
stent placement. Fifteen (21%) patients developed stent mal-
function after 30 days, requiring re-intervention. 
Stent patency
Cumulative stent patency analyzed by the Kaplan-Meier meth-
od is depicted in Fig. 2, and median stent patency was 108 days. 
Univariate analysis showed Bismuth type IV (vs. II, III), imme-
diate complication, and baseline bilirubin (>6.1 mg/dL) to be 
predictors of stent occlusion (all p<0.1). To avoid potential mul-
ticollinearity and to consider the possibility of immediate com-
plication as procedure-related complication, immediate com-
plication and bismuth type were separately incorporated into 
multivariate analyses. After adjusting for other variables, high 
bilirubin level (>6.1 mg/dL) was identified as an independent 
predictor of stent obstruction (Table 3). In this study, although 
results indicated immediate complication as an independent 
risk factor related to stent patency, it could be considered as a 
confounding factor in some respect. In addition, we reana-
lyzed the results after excluding patients with immediate com-
plication, as shown in Supplementary Tables 1 and 2 and Sup-
plementary Figs. 1 and 2 (only online). In the present study, we 
selected the median value (6.1 mg/dL) of pre-stenting total 
bilirubin as a cut-off level for predicting stent occlusion and 
overall survival. No statistically significant difference in stent 
patency was observed between the two centers (p=0.114). For 
comparison, median stent patency rates reported by previous 
studies are shown in Supplementary Table 3 (only online).
 
Overall survival
Cumulative survival analyzed by the Kaplan-Meier method is 
Table 1. Baseline Clinical Characteristics of Patients (n=70)
Variables Values
Sex (male/female) 38/32
Age (yr) 68.0±12.3
Diagnosis
Cholangiocarcinoma 37 (52.9)
Gallbladder cancer 22 (31.4)
Others* 11 (15.7)
Bismuth classification
II 13 (18.6)
III 17 (24.3)
IV 40 (57.1)
Previous stenting 27 (38.6)
Plastic 26 (37.1)
Metal 1 (1.4)
Baseline total bilirubin (mg/dL) 6.1±11.1
Total bilirubin level after 4 weeks (mg/dL) 1.2±1.7
Baseline ALP (IU/dL) 450.0±354.8
Antitumor treatment
Yes 38 (56.4)
No 32 (43.6)
ALP, alkaline phosphatase.
Variables are expressed as median±SD or n (%).
*Others include pancreatic cancer (n=7) and gastric cancer (n=4). 
Table 2. Clinical Outcomes of Bilateral Metal Stents (n=70)
Outcomes Values 
Technical success 69 (98.0)
Functional success 59 (85.5)
Immediate complications*
Cholecystitis 0 (0)
Cholangitis 4 (5.6)
Liver abscess 0 (0)
Pancreatitis 5 (7.0)
Stent malfunction 0 (0.0)
Early complications*
Cholecystitis 0 (0)
Cholangitis 8 (11.2)
Liver abscess 0 (0)
Pancreatitis 0 (0)
Stent malfunction 3 (3.2)
Late complications
Cholangitis 0 (0)
Stent malfunction 15 (21.0)
Stent occlusion 35 (50.0)
Ingrowth 29/35 (82.8)
Overgrowth 2/35 (5.7)
Sludge 1/35 (2.9)
Unknown 3/35 (8.6)
Follow up period (days) 140 [57–329]
Survival (days) 181 [66–376]
Variables are expressed as median [interquartile range] or n (%).
Stent malfunction was defined when re-intervention was needed in cases of 
complications, such cholangitis and/or jaundice, elevated liver enzyme lev-
els, and bile duct dilation compared with previous CT images.
*Immediate complication, within 72 h of stent placement; early complication, 
after 72 h but within 30 days of stent placement.
831
Ja Yoon Heo, et al.
https://doi.org/10.3349/ymj.2018.59.7.827
shown in Fig. 3, and median survival time was 181 days. Cumu-
lative survival was significantly better in patients with antitu-
mor therapy than in those without, according to univariable 
Cox proportional hazards analysis [hazard ratio (HR) 0.56, 
95% confidence interval (CI) 0.320–0.981; p=0.043]. In addi-
tion, patients with a pre-stenting bilirubin level of >6.1 mg/dL 
Fig. 2. Cumulative stent patency of bilateral hilar metal stent as analyzed 
by Kaplan-Meier curves. Median survival time analyzed by the Kaplan-
Meier method was 108 days.
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Table 3. Independent Factors Associated with Stent Patency of Bilateral Hilar Metal Stents in Cox Regression Analysis
Variables
Univariate analysis Multivariate analysis* Multivariate analysis†
HR 95% CI p value Adjusted HR 95% CI p value Adjusted HR 95% CI p value
Female 0.863 0.420–1.777 0.690
Age <70 years 0.570 0.278–1.169 0.125
Bismuth type IV vs. II, III 1.096 0.149–1.083 0.071 1.265 0.635–2.520 0.505 1.173 0.575–2.395 0.661
Antitumor therapy 1.132 0.509–2.517 0.760
Immediate complication‡ 3.628 1.329–9.903 0.012 3.633 1.423–9.272 0.007
Baseline bilirubin >6.1 mg/dL 2.586 1.215–5.507 0.014 1.936 0.938–3.996 0.074 2.606 1.223–5.553 0.013
HR, hazard ratio; CI, confidence interval.
*Immediate complication was incorporated into multivariate analysis, †Immediate complication was not incorporated into multivariate analysis, ‡Immediate 
complication: within 72 h of stent placement.
Fig. 3. Kaplan-Meier curve of patient overall survival after placement of 
bilateral metal stent. Median survival time analyzed by Kaplan-Meier 
method was 181 days. 
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Table 4. Independent Factors Associated with Survival after Placement of Bilateral Hilar Metal Stents in Cox Regression Analysis
Variables
Univariate analysis Multivariate analysis
HR 95% CI p value Adjusted HR 95% CI p value
Female 0.964 0.737–1.261 0.790
Age <70 years 0.976 0.574–1.658 0.928
Bismuth type IV vs. II, III 1.139 0.626–2.071 0.305
Antitumor therapy 0.560 0.320–0.981 0.043 0.658 0.365–1.186 0.164
Immediate complication* 0.927 0.395–2.178 0.862
Baseline bilirubin >6.1 mg/dL 2.150 1.181–3.914 0.012 1.780 0.937–3.383 0.078
HR, hazard ratio; CI, confidence interval.
*Immediate complication: within 72 h of stent placement.
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had worse survival than those with values <6.1 mg/dL in uni-
variable Cox proportional hazard analysis (HR 2.15, 95% CI 
1.181–3.914; p=0.012). However, neither antitumor therapy nor 
bilirubin level was a statistically significant prognostic factor 
in multivariate analysis (Table 4).
DISCUSSION
Endoscopic biliary drainage is a major strategy for MHBO as it 
is a less invasive, more convenient, and a more physiological 
procedure, compared to a percutaneous approach or surgical 
bypass.18,19 Previous studies have reported median stent pa-
tency rates ranging from 134 to 238 days (Supplementary Table 
3, only online). In the present study, stent patency duration 
and median overall survival rate were shorter than those re-
ported in previous studies (108 days and 181 days, respective-
ly). The results could be explained by a difference in the pro-
portion of high-grade hilar biliary obstructions in the present 
study (Bismuth type IV, 57.1%), as patients with high-grade 
biliary obstruction are at high risk for recurrent biliary drain-
age.20 
It is important to know the risk factors associated with short 
stent patency in SIS method. In the present study, a pre-stent-
ing higher total bilirubin level and the presence of immediate 
complications were independent risk factors related to stent 
patency duration in patients with MHBO. To evaluate the vari-
able factors that influence stent patency, Naitoh, et al.12 report-
ed that antitumor therapy was associated with a significantly 
longer stent patency in multivariable analysis, even if the dif-
ference was not statistically significant in the present study. 
Miura, et al.20,21 reported that baseline bilirubin and cholangi-
tis before SEMS placement were risk factors for recurrent bili-
ary obstruction after SEMS placement in patients with MHBO. 
Higher total bilirubin reflects progression of tumor, and ad-
vanced tumor is likely to occlude inside of metal stent. Fur-
thermore, patients with immediate complications eventually 
presented with cholangitis with occlusion. Only 56.4% of pa-
tients received chemotherapy, which could have an effect on 
patient survival. In univariate analysis, antitumor treatment 
was an independent factor related to survival; however, multi-
variable analysis did not confirm the result. In patients who are 
diagnosed with cholangiocarcinoma, the most common cause 
of death is infectious complication related to bile duct obstruc-
tion, such as biliary sepsis.22,23 Therefore, after adjusting for bile 
duct obstruction related factors, antitumor treatment might 
not be an independent prognostic factor. 
A previous study showed that one of the problems of the SIS 
method, compared to side-by-side (SBS) method, may be 
short stent patency. However, in regards to stent patency of the 
SIS method, comparison to the SBS method is still controver-
sial.12,13 To date, there are no randomized controlled trials com-
paring SBS and SIS. Regarding SIS method, previous studies 
showed discrepancy in the duration of stent patency.6,9-15,24,25 A 
major problem of these previous retrospective studies was a 
difference in the mechanical properties of SEMSs, with vari-
ous high axial and radial forces.26-28 Also, there were differenc-
es in the definitions of stent occlusion, such as biliary obstruc-
tion or patient death, for those without biliary obstruction. If 
obstruction was not evident during a patient’s life, patency pe-
riod was equal to survival period, but with censored data. In 
contrast, some studies have shown the median duration of bili-
ary obstruction after stent insertion. 
This study had several limitations. First, this study was a non-
randomized, retrospective study with a small sample size. 
However, since tumors of the biliary tract are relatively uncom-
mon, 70 patients is a decent sample size for this particular pop-
ulation, and 70 patients with malignant hilar obstruction is 
quite a large sample size. Therefore, the present study does hold 
clinical relevance. Secondly, this study was not a comparative 
study between groups. However, the present study was per-
formed in two large-volume centers, where biliary drainage 
was mostly done, using the SIS method in unresectable MHBO. 
Therefore, this study could minimize selection bias between 
SIS and SBS methods. 
In conclusion, higher baseline bilirubin (>6.1 mg/dL) was 
found to be an independent risk factor related to stent paten-
cy. The SIS method still remains a controversial option with 
short stent patency for high-grade MHBO. Further studies are 
required to improve stent patency using new methods or 
newly designed stents in patients with high-grade biliary ob-
struction with severe jaundice.
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